Search research articles
Contact Us
Filters
Showing results (11-20 of 41) with videos related to
Page
of 5
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
August 2, 2017
High-risk Multiple Myeloma: Definition and Management
Nisha S Joseph, Silvia Gentili, Jonathan L Kaufman, et al.
Frontiers in Oncology
|
February 26, 2021
Game of Bones: How Myeloma Manipulates Its Microenvironment
Tyler Moser-Katz, Nisha S Joseph, Madhav V Dhodapkar, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
May 28, 2026
High-Risk Multiple Myeloma: Redefining Risk and Rethinking Therapy
Gareth J Morgan, Dennis D Lee, Nisha S Joseph, et al.
Cancer
|
May 16, 2019
Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients
Ajay K Nooka, Nisha S Joseph, Jonathan L Kaufman, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 31, 2026
The Evolution of Chimeric Antigen Receptor T-Cell, Bispecific Antibodies and Antibody-Drug Conjugates for the Treatment of Multiple Myeloma
Lorenzo Cani, Richa Parikh, Nisha S Joseph, et al.
Blood Cancer Journal
|
February 22, 2023
Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience
Kathryn T Maples, Kevin H Hall, Nisha S Joseph, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 9, 2025
Feasibility and Safety of Outpatient Model for Administration of Bispecific Antibodies: Proceedings from an International Myeloma Society 21st Annual Meeting Oral Abstract
Sara A Scott, Danielle L Roberts, Vikas A Gupta, et al.
Haematologica
|
September 4, 2025
Infection risk in 158 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies: a single-center experience
Lorenzo Cani, Sara A Scott, Danielle Roberts, et al.
Blood Cancer Journal
|
September 13, 2024
Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients
Nisha S Joseph, Jonathan L Kaufman, Vilas A Gupta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 17, 2020
Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma
Nisha S Joseph, Jonathan L Kaufman, Madhav V Dhodapkar, et al.
Page
of 5
Search research articles
Search
Showing results (11-20 of 41) with videos related to
Sort By:
Page
of 5
Clinical Lymphoma, Myeloma & Leukemia
|
August 2, 2017
High-risk Multiple Myeloma: Definition and Management
Nisha S Joseph, Silvia Gentili, Jonathan L Kaufman, et al.
Frontiers in Oncology
|
February 26, 2021
Game of Bones: How Myeloma Manipulates Its Microenvironment
Tyler Moser-Katz, Nisha S Joseph, Madhav V Dhodapkar, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
May 28, 2026
High-Risk Multiple Myeloma: Redefining Risk and Rethinking Therapy
Gareth J Morgan, Dennis D Lee, Nisha S Joseph, et al.
Cancer
|
May 16, 2019
Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients
Ajay K Nooka, Nisha S Joseph, Jonathan L Kaufman, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 31, 2026
The Evolution of Chimeric Antigen Receptor T-Cell, Bispecific Antibodies and Antibody-Drug Conjugates for the Treatment of Multiple Myeloma
Lorenzo Cani, Richa Parikh, Nisha S Joseph, et al.
Blood Cancer Journal
|
February 22, 2023
Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience
Kathryn T Maples, Kevin H Hall, Nisha S Joseph, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 9, 2025
Feasibility and Safety of Outpatient Model for Administration of Bispecific Antibodies: Proceedings from an International Myeloma Society 21st Annual Meeting Oral Abstract
Sara A Scott, Danielle L Roberts, Vikas A Gupta, et al.
Haematologica
|
September 4, 2025
Infection risk in 158 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies: a single-center experience
Lorenzo Cani, Sara A Scott, Danielle Roberts, et al.
Blood Cancer Journal
|
September 13, 2024
Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients
Nisha S Joseph, Jonathan L Kaufman, Vilas A Gupta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 17, 2020
Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma
Nisha S Joseph, Jonathan L Kaufman, Madhav V Dhodapkar, et al.
Page
of 5